[REVIEW] "In 2017 the world's top ten anticancer drugs, there are six bio-medicine. Our innovative biopharmaceuticals relatively close to the international advanced level."

"Significant Drug Discovery" national science and technology major projects launched in 2008, the implementation period from 2008 to 2020. Major projects soon to wrap up the people's livelihood, how the results?

Photos from the network

"Create new drugs special output a number of major landmark achievement, achieved remarkable economic and social benefits." July 31, in conjunction with the Ministry of Health health committee held a "significant Drug Discovery" science and technology major special press conference in Beijing, Science and Technology Ministry of major projects, deputy director Yang Zhe representation.

Special creation of new drugs Implementation Management Office Deputy Director, Science and Education Committee Secretary Liu Dengfeng health commissioner introduction: "Since 2017, there are 14 approved class of drugs, showing growth spurt."
Since the special launch, China's number of new drugs approved?

Since the creation of new drugs special start, as of July this year, a total of 139 special varieties of new drug certificate, in which a class of drugs 44, is eight times the number before the specific implementation. Demand for the prevention and control of major diseases, drug created special industrial chain around the chain to deploy R & D, research and development of major species and remarkable achievements have been exceeded "Thirteen Five" variety research and development objectives.
The number of new drugs not only variety, quality level is very high. With antineoplastic agents, for example, PD-1 immunotherapy research won the 2018 Nobel Prize. Immunotherapy against cancer cells by activating the body's own immune system to adapt to a wide range of side effects, is a revolutionary therapy.
"In 2017 the world's top ten anticancer drugs, there are six bio-medicine. Our innovative biopharmaceuticals relatively close to the international advanced level." Drug created special technology division vice president Academician Chen Kaixian, since 2018, a total of 3 approved a PD-1 inhibitors, namely Teruipuli mAb, mAb letter Dealy, Karui Li daclizumab. "The PD-1 inhibitor drugs on the market, pushing the country into the era of immunotherapy."
"Create new drugs aimed at foreign special frontier medicine." Vice president of Chinese Academy of Medical Sciences Cancer Hospital Shi Yuankai said that since the beginning of 2018, China approved the PD-1 drugs on the market, allowed just six months in the Chinese market in the first two kinds of PD-1 drugs abroad inside, China's self-developed PD-1 drugs, such as real organisms Teruipuli Jun monoclonal antibody, Cinda bio-letter Dealey monoclonal antibody approved on the market. "These drugs to cancer patients brought our new treatment options. At present, there are some PD-1 / PD-L1 monoclonal antibody drugs in clinical trials, is worth the wait."
Biological research and development of innovative drugs usually go through long years of grinding, listed medicines road road resistance and long. China's bio-pharmaceutical industry started relatively late, after 2008, a large number of overseas talent has served on the internationally renowned pharmaceutical companies have come back, greatly promoted the process of internationalization of the total had biological drugs.
In 2020, a special ending soon create new drugs, new drug development will also usher in a new orientation and tasks. Chen Kaixian Academy of Sciences said that the future will strengthen multi-disciplinary, multi-technology integration methods intersection, to connect the forefront of technology breakthroughs, new drug research and industrial development to develop new directions and, ultimately, meet the people "lingua franca, affordable," the demand for drugs contribute.

[Source: Instrument Information] Editor: Li Zhaokun